Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The FDA approved Vertex Pharmaceuticals’ gene therapy Casgevy for treating beta thalassemia, an inherited blood disease that leads to low levels of functioning hemoglobin. Last month ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

Learn how CASGEVY, the first NHS-approved CRISPR gene therapy, treats sickle cell disease through a revolutionary genetic ...

Additionally, shares of Vertex Pharmaceuticals have surged 14.7% ... patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY, creating a positive sentiment, and its shares jumped 5.3% ...

Biotech company Vertex Pharmaceuticals (NASDAQ ... the continuing global launch of CASGEVY; and multiple ongoing pivotal trials. We are excited to drive diversification of the revenue base ...

Vertex Pharmaceuticals (Nasdaq ... patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute ...